These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 26929417)
1. The role of moxifloxacin in tuberculosis therapy. Gillespie SH Eur Respir Rev; 2016 Mar; 25(139):19-28. PubMed ID: 26929417 [TBL] [Abstract][Full Text] [Related]
2. Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations? Yew WW; Koh WJ Korean J Intern Med; 2016 Jan; 31(1):15-29. PubMed ID: 26767853 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of moxifloxacin combined with levofloxacin in the treatment of drug-resistant tuberculosis. Qiujing F; Weiwei W Pak J Pharm Sci; 2020 May; 33(3(Special)):1361-1366. PubMed ID: 33361023 [TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone resistance in Mycobacterium tuberculosis. What have we learnt? Yew WW; Lange C Int J Tuberc Lung Dis; 2014 Jan; 18(1):1-2. PubMed ID: 24365543 [No Abstract] [Full Text] [Related]
5. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
6. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis. Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478 [TBL] [Abstract][Full Text] [Related]
8. Fluoroquinolones for the treatment of tuberculosis in children. Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS Tuberculosis (Edinb); 2015 May; 95(3):229-45. PubMed ID: 25797610 [TBL] [Abstract][Full Text] [Related]
9. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076 [TBL] [Abstract][Full Text] [Related]
10. [Present and future in the use of anti-tubercular drugs]. Didilescu C; Craiova UM Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168 [TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolones for the treatment of pulmonary tuberculosis. Moadebi S; Harder CK; Fitzgerald MJ; Elwood KR; Marra F Drugs; 2007; 67(14):2077-99. PubMed ID: 17883288 [TBL] [Abstract][Full Text] [Related]
12. How are we creating fluoroquinolone-resistant tuberculosis? Bernardo J; Yew WW Am J Respir Crit Care Med; 2009 Aug; 180(4):288-9. PubMed ID: 19661251 [No Abstract] [Full Text] [Related]
13. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909 [TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis. Chen Z; Liang JQ; Wang JH; Feng SS; Zhang GY Tuberculosis (Edinb); 2015 Jul; 95(4):490-6. PubMed ID: 25964137 [TBL] [Abstract][Full Text] [Related]